Cara Therapeutics Inc (CARA) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.48 earnings per share for the quarter, missing the analyst consensus estimate by $-0.07. Analysts had a consensus of $-0.41. The company posted revenue of $.08 million in the period, compared to analysts expectations of $.13 million. The company’s revenue was down -91.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.25 EPS.
Cara Therapeutics Inc closed down -0.26 points or -4.30% at $5.78 with 6,96,067 shares getting traded on Tusday. Post opening the session at $6.04, the shares hit an intraday low of $5.51 and an intraday high of $6.1125 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Apr 20, 2016, Frederique Ph.d. Menzaghi (VP-Research & Development) sold 6,000 shares at $9.00 per share price. According to the SEC, on Jan 27, 2016, Michael E Lewis (Chief Scientific Advisor) sold 7,262 shares at $10.93 per share price. On Jan 12, 2016, Dean Slagel (director) sold 44,000 shares at $17.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Cara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes with no off-target activities.